Anthony Bergmann; Chief Financial Officer; Capricor Therapeutics Inc. Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc. Edward T ...
RGX-202, a DMD gene therapy, has been well tolerated in an ongoing clinical trial and improved motor function for DMD boys, ...
The warning comes amid reports that unregulated therapies are being offered directly to patients, potentially illegally.
Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study, which is examining ...
ROCKVILLE, MD, USA I March 19, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase ...
Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...
Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...
Satellos Bioscience Inc. ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today ...
A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...
A young man with Duchenne MD and treated with Elevidys has died of acute liver failure, Sarepta reports; it's working with ...
Precision BioSciences (DTIL) announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of ...
The company plans to submit a biologics licence application to the US Food and Drug Administration later this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback